Consequently, we believe that TGFBR2 represents an ideal target to act against elevated TGFβ concentrations as found in in the context of neurodegenerative disorders, such as ALS, or also in several other diseases like IPF or in immune oncology. This evidence concerns the gene TGFB1 and amyotrophic lateral sclerosis.